Target intelligence / Profile preview

Immunoglobulin heavy diversity 1-1 (IGHD1-1)

Target
IGHD1-1
Molecular classification
Other (immunoglobulin gene segment), Immunoglobulin diversity segment
01

Overview

Immunoglobulin heavy diversity 1-1 (IGHD1-1) is one of multiple diversity (D) gene segments in the human immunoglobulin heavy chain locus, located on chromosome 14q32. These D segments are critical for the generation of antibody diversity, as they are recombined with variable (V) and joining (J) segments during B-cell development. This recombination process, known as V(D)J recombination, allows B lymphocytes to produce a vast array of different immunoglobulins with distinct antigen specificities. The IGHD1-1 segment itself encodes part of the antigen-binding site of the immunoglobulin heavy chain[1][2][3]. It is a DNA segment, not an expressed protein or receptor. Variation in the IGH locus, including IGHD1-1, contributes to differences in immune function and disease susceptibility but is not itself a functional protein or receptor amenable to drug targeting[1][3]. IGHD1-1 is often confused with immunoglobulin heavy chain constant regions or actual immunoglobulin receptors, which are functional proteins targeted by therapeutics (e.g., anti-IgG therapies). IGHD1-1 is a genetic segment; its main function is to contribute genetic diversity in antibodies, not to serve as a drug target or biomarker itself. A query that seeks a receptor, enzyme, or other classical target should not map IGHD1-1 as a valid or actionable therapeutic target[1][3][4].

Other names
IGHD1-1IGHD11HD101
02

Biological functions

Adaptive immune responseImmunoglobulin diversity (antibody repertoire generation)
03

Disease associations

Other (variation in the IGH locus may influence responses in autoimmunity, infection, vaccine efficacy, and possibly cancer, but IGHD1-1 has no direct disease role by itself)

Beyond the preview

Go deeper on Immunoglobulin heavy diversity 1-1 (IGHD1-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin heavy diversity 1-1 (IGHD1-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call